In Brief

FreeIn Brief

Tempus, Abramson Cancer Center collaborate on immunotherapy

TEMPUS, a technology company focused on supporting physicians delivering customized cancer care, and the University of Pennsylvania Abramson Cancer Center partnered to better determine which patients will have a positive response to immunotherapy treatment based on next generation genomic and transcriptomic sequencing. As part of a research collaboration, Tempus will provide sequencing and analysis of […]